WO2003005991A1 - A core formulation - Google Patents
A core formulation Download PDFInfo
- Publication number
- WO2003005991A1 WO2003005991A1 PCT/US2001/021676 US0121676W WO03005991A1 WO 2003005991 A1 WO2003005991 A1 WO 2003005991A1 US 0121676 W US0121676 W US 0121676W WO 03005991 A1 WO03005991 A1 WO 03005991A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- glucopyranosyl
- patient
- core
- metformin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- any one of the biguanides i.e. drugs having the action of the stimulation of anaerobic glycolysis
- these, like metformin increase the sensitivity to insulin in peripheral tissues of the host, e.g. a human being or another animal.
- These compounds also are involved in the inhibition of glucose absorption from the intestine, suppression of hepatic gluconeogenesis, and inhibition of fatty acid oxidation.
- Examples of other typical biguanides included in this application are phenformin, buformin etc.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001273310A AU2001273310B2 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
JP2003511799A JP2004536841A (en) | 2001-07-10 | 2001-07-10 | Core preparation |
CA002453784A CA2453784A1 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
PCT/US2001/021676 WO2003005991A1 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
EP01952575A EP1429732A4 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
MXPA04000176A MXPA04000176A (en) | 2001-07-10 | 2001-07-10 | A core formulation. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/021676 WO2003005991A1 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003005991A1 true WO2003005991A1 (en) | 2003-01-23 |
Family
ID=21742691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021676 WO2003005991A1 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1429732A4 (en) |
JP (1) | JP2004536841A (en) |
AU (1) | AU2001273310B2 (en) |
CA (1) | CA2453784A1 (en) |
MX (1) | MXPA04000176A (en) |
WO (1) | WO2003005991A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429747A1 (en) * | 2001-07-10 | 2004-06-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
WO2004069229A1 (en) * | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Dual release anti-diabetic drugs and process of production thereof |
AU2001273310B2 (en) * | 2001-07-10 | 2004-10-07 | Kos Life Sciences, Inc. | A core formulation |
WO2004091587A1 (en) * | 2003-04-17 | 2004-10-28 | Ipca Laboratories Limited | Multiple release anti-diabetic drugs and process of production thereof |
WO2005065663A1 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
WO2010136847A1 (en) * | 2009-05-26 | 2010-12-02 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Coated metformin with pioglitazone solution |
JP2014196314A (en) * | 2003-09-19 | 2014-10-16 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | Novel pharmaceutical formulation containing biguanide and thiazolidinedione derivative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929101A (en) * | 1990-02-09 | 1999-07-27 | Pharmacia & Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
US6191162B1 (en) * | 1998-05-28 | 2001-02-20 | Medical Research Institute | Method of reducing serum glucose levels |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
US6780432B1 (en) * | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
CA2453775A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
CA2453784A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | A core formulation |
-
2001
- 2001-07-10 CA CA002453784A patent/CA2453784A1/en not_active Abandoned
- 2001-07-10 EP EP01952575A patent/EP1429732A4/en not_active Withdrawn
- 2001-07-10 MX MXPA04000176A patent/MXPA04000176A/en unknown
- 2001-07-10 WO PCT/US2001/021676 patent/WO2003005991A1/en not_active Application Discontinuation
- 2001-07-10 JP JP2003511799A patent/JP2004536841A/en active Pending
- 2001-07-10 AU AU2001273310A patent/AU2001273310B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929101A (en) * | 1990-02-09 | 1999-07-27 | Pharmacia & Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
US6191162B1 (en) * | 1998-05-28 | 2001-02-20 | Medical Research Institute | Method of reducing serum glucose levels |
Non-Patent Citations (1)
Title |
---|
See also references of EP1429732A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429747A1 (en) * | 2001-07-10 | 2004-06-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
AU2001273310B2 (en) * | 2001-07-10 | 2004-10-07 | Kos Life Sciences, Inc. | A core formulation |
EP1429747A4 (en) * | 2001-07-10 | 2005-01-05 | Kos Life Sciences Inc | Core formulation comprising pioglitazone hydrochloride and a biguanide |
WO2004069229A1 (en) * | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Dual release anti-diabetic drugs and process of production thereof |
WO2004091587A1 (en) * | 2003-04-17 | 2004-10-28 | Ipca Laboratories Limited | Multiple release anti-diabetic drugs and process of production thereof |
JP2014196314A (en) * | 2003-09-19 | 2014-10-16 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | Novel pharmaceutical formulation containing biguanide and thiazolidinedione derivative |
WO2005065663A1 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
WO2010136847A1 (en) * | 2009-05-26 | 2010-12-02 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Coated metformin with pioglitazone solution |
Also Published As
Publication number | Publication date |
---|---|
EP1429732A4 (en) | 2005-01-26 |
EP1429732A1 (en) | 2004-06-23 |
AU2001273310B2 (en) | 2004-10-07 |
CA2453784A1 (en) | 2003-01-23 |
MXPA04000176A (en) | 2004-10-27 |
JP2004536841A (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6524621B2 (en) | Core formulation | |
US6403121B1 (en) | Core formulation | |
US6451342B2 (en) | Core formulation comprised of troglitazone and a biguanide | |
US6780432B1 (en) | Core formulation | |
US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
CA2470581C (en) | Antidiabetic formulation and method | |
US20060141023A1 (en) | Pharmaceutical compositions containing abiguanide-glitazone combination | |
IL158506A (en) | Oral pharmaceutical form for a single daily intake combining a metformin and at least one other antidiabetic active principle | |
US6461639B2 (en) | Core formulation | |
MXPA02004282A (en) | Pharmaceutical composition comprising a combination of metformin and glibenclamide. | |
AU2001273310B2 (en) | A core formulation | |
AU2001273289B2 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
AU2001273310A1 (en) | A core formulation | |
AU2001257456B2 (en) | A core formulation | |
AU2001273289A1 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
AU2001257456A1 (en) | A core formulation | |
AU2001273290B2 (en) | Core formulation comprising troglitazone and a biguanide | |
AU2001273290A1 (en) | Core formulation comprising troglitazone and a biguanide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000176 Country of ref document: MX Ref document number: 2453784 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001952575 Country of ref document: EP Ref document number: 2003511799 Country of ref document: JP Ref document number: 2001273310 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001952575 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001273310 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001952575 Country of ref document: EP |